Feature

Video: Reducing Injections in Wet AMD

Avni Finn, MD, and Diana V. Do, MD, discuss promising results from the DAVIO2 trial of EYP-1901.

Share

Dr. Avni Finn presented key insights at the 2025 American Society of Retina Specialists Annual Meeting, revealing promising results from the DAVIO2 trial involving EYP-1901, a novel tyrosine kinase inhibitor designed to reduce the treatment burden for patients with wet macular degeneration. Traditionally, patients endure frequent anti-VEGF injections to maintain vision; however, the trial demonstrated that with EYP-1901, patients significantly reduced their injection frequency from an average of 10 to just 1 or 2 supplemental injections per year. This innovation could transform treatment practices, enhancing patient compliance and outcomes.

Original Source(s)

Video: Reducing Injections in Wet AMD

Avni Finn, MD, and Diana V. Do, MD, discuss promising results from the DAVIO2 trial of EYP-1901.

  • by Avni Finn, MD, MBA, Diana V. Do, MD

  • July 14, 2025

  • 2 min

Related Content

EYP-1901 for Retinal Exudative Diseases

An overview of the current status of the EYP-1901 clinical trial program in wet AMD and DME, presented at Hawaiian Eye and Retina 2026

When the Kidney Meets the Retina

New study suggests potential causal link between kidney disease and AMD

  • January 22, 2026

  • 3 min
Coding Q&A: Coding Guidelines for Wet AMD

Proper use of ICD-10-CM codes ensures compliance and prompt payment.